Suven Life Sciences share news, announcements and annual reports
NSE: SUVENBSE: 530239Healthcare ServicesSmall Cap
Suven Life Sciences Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1995 on BSE, Oct 2003 on NSE
Last close ₹271.75up ₹12.90 (4.98%)BSE ₹271.75
Share price at the NSE close on 2 Nov 2026. Previous close ₹258.85.
2 Nov: open ₹260.10, high ₹275.50, low ₹256.30
52-week range of traded prices to 2 Nov 2026
₹124.11Low, 24 Mar 2026₹403.35High, 1 Sep 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹7,679 Cr806th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −100.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −63.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 4,18,38627.5% delivered
Suven Life Sciences share news and announcements
803 announcements, routine notices left out, newest first. Page 16 of 17.
May 2008
27 May · Business
Press release dated May 27, 2008, titled "Suven Life Sciences gets Two product patents for NCEs in Russia and Australia". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 May · Business
Press release dated May 20, 2008, titled "Suven Life Sciences gets Two product patents for NCEs in South Africa and China". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 May · Business
Press release dated May 05, 2008, titled "Suven's Clinical Candidate SUVN-502 Secures European product patent". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2008
26 Apr · News Release
News release dated April 26, 2008, titled "Revenue growth at 7.44%, R&D spent at 24.53% of Revenue; 17 Product Patents obtained during the qtr globally; Establishes Second CNS Drug Discovery collaboration with Lilly". A copy of the news release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 Apr · Board meeting
Inter alia, to consider and take on record the Un-audited Financial Results for the Quarter ended March 31, 2008.8 Apr · Business
Press release dated April 08, 2008, titled "Suven Life Sciences' ACT Enters into an Alliance with VPSCRO". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2008
31 Mar · Business
Press release dated March 31 , 2008, titled "Suven Life Sciences gets Two product patents in Korea and Mexico". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.24 Mar · Business
Press release dated March 24 , 2008, titled "Suven Life Sciences secures Two Products Patents in all Russian countries (Eurasia Region)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.12 Mar · Business
Press release dated March 12 , 2008, titled "Suven Establishes Second CNS Drug Discovery Collaboration with Lilly". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2008
8 Feb · Allotment of Equity Shares
The Compensation committee of Board of Directors of the company allotted 78,540 equity shares through circular resolution on 8th February, 2008 under stock option plan of the company. Further consequent to the above allotment, paid up share capital of the company has gone up from 115631660 equity shares of Re 1/- each aggregating Rs. 115631660 to 115710200 equity shares of Re 1/- each aggregating Rs 115710200/-
Jan 2008
28 Jan · Grant of Stock Options
The Compensation committee in its meeting held on 28th January, 2008 had granted 2,00,000 stock options to the eligible employees of the Company under Suven employees stock options plan-200428 Jan · News Release
News release dated January 28, 2008, titled "Suven Revenue stands flat, R&D spent at 25% of Revenue; Obtains 2 US, 3 European and 4 Indian Product Patents during the qtr". A copy of the news release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.23 Jan · Business
Press release dated January 23, 2008, titled "Suven Obtains 2nd Product Patent from US Patent office". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Jan · Board meeting
Meeting on 28 Jan 2008: “Unaudited Financial Results for the qtr ended Dec 31, 2007”
Dec 2007
27 Dec · Business
Press release dated December 27, 2007, titled "Suven Obtains 1st Product Patent from US Patent office". A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Dec · Raising of Funds
Company's Vice- Chairman & CEO Mr. Venkat Jasti held discussion today i.e. December 18, 2007 with some of the news papers and media persons on the business models of company and about the various fund raising options such as FCCBs/ADRs/GDRs etc for the purpose of meeting its R&D expenditure for conducting Clinical Trials of company's New Chemical Entities and for creation of dedicated Drug Discovery Centre, in pursuance of resolution approved by the members in AGM held on September 27, 2007.11 Dec · Business
Press release dated December 11, 2007 titled "Suven presenting at Windhover's Bio/Pharma Partnerships conference in San Francisco". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Nov 2007
27 Nov · Business
Press release dated November 27, 2007, titled "Suven Life Sciences secures two Product Patents from European Patent Office (EPO) for the treatment of Neurodegenerative diseases". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.12 Nov · Allotment of Equity Shares
The Compensation committee of Board of Directors of the company allotted 3,65,160 Equity shares of Re.1/- each through circular resolution on November 12, 2007 under stock option plan of the company. Further consequent to the above allotment, paid up capital of the company has gone up from 11,52,66,500 equity shares of Re 1/- each aggregating Rs 11,52,66,500 to 11,56,31,660 shares of Re 1/- each aggregating Rs 11,56,31,660/-7 Nov · News Release
News release dated October 30, 2007, titled "Suven's half yearly revenues increase by 10%, R & D spent at 26% of Revenue". A copy of the news release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements) For more details click here.5 Nov · Business
Press release dated November 05, 2007, titled "Suven Life Sciences presenting Pre-clinical data of their NCEs at Society for Neuroscience Annual Meeting, SFN-2007 at San Diego, USA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2007
31 Oct · Business
Press release dated October 31, 2007, titled "Suven Life Sciences secures Two (2) Product Patents in Australia & New Zealand for Their New Chemical Entities (NCEs)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.25 Oct · Business
Press release dated October 25, 2007, titled "Suven enters into collaboration with University of Minnesota to develop Drugs to treat HIV infection". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.23 Oct · News Release
News Release dated October 23, 2007 titled as "Suven Life Sciences secures Three (3) Indian Product Patents For Their New Chemical Entities (NCEs) ". The copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Oct · Board meeting
Meeting on 30 Oct 2007: “Unaudited Financial Results for the Qtr ended Sept 30, 2007”
Sep 2007
27 Sep · Meeting
The members in Annual General Meeting (AGM) held on 27th September 2007 have declared the Dividend @25% for the year 2006-07 and also approved and authorized the Board of Directors to raise funds to the tune of USD 50 million either through international offering and / or domestic offering by way of FCCBs/ADRs/GDRs etc. The Board of Directors in their meeting held on 27th September 2007 have taken on record and approved the Cost Accounts of the Company for the year 2006-0718 Sep · Board meeting
To consider and approve Cost Accounts of the Company for the year 2006-07.
Aug 2007
1 Aug · News Release
News Release dated July 31, 2007 titled as "Suven PAT up by 51%; R & D spend at 33% of Revenue". The copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2007
31 Jul · Miscellaneous
Brief financials as required to be furnished under clause 20 for the Current year ended March 31, 2007. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.31 Jul · Raising of Funds
Board in its meeting held on July 31, 2007 considered and approved to raise funds to the tune of 50 Million USD or its equivalent of any other Foreign /Indian currencies either by way of international offerings and / or domestic offerings for purpose of meeting its R&D expenditure for conducting Clinical Trials upto proof of concept (Phase 2) of the Company's New Chemical Entity (NCE) SUVN-502 for Alzheimer's decease and for creation of dedicated Drug Discovery Centre, subject to necessary consents/approvals.31 Jul · Dividend
Board at its meeting held on July 31, 2007 has recommended a dividend of Rs. 0.25 per share (25%) on the face value of Rs.1 each for the year 06-07.31 Jul · Meeting
Board in its meeting held on July 31, 2007, recommended Dividend @ 25% p.a. for the financial year ended March 31, 2007, subject to the approval of Members in ensuing Annual General Meeting. Further the Company has informed that the Register of Members and Share Transfer Books will be closed from September 25, 2007 to September 27, 2007 for the purpose of AGM and Dividend Declaration. The AGM will be held on September 27, 2007.23 Jul · Board meeting
To consider, inter alia, and take on record the following matters: (1) To consider and approve the Annual Accounts for the year ended March 31, 2007. (2) To recommend dividend for the financial year ended March 31, 2007 subject to approval of Shareholders at the ensuing AGM. (3) To announce Book Closure for the purpose of AGM and distribution of Dividend. (4) To consider and take on record the Un-audited Financial Results for the First Quarter ended June 30, 2007.12 Jul · Business
Press release dated July 12, 2007, titled "Suven Life Sciences files its first Investigational New Drug (IND) application of its NCE SUVN-502 in India to conduct Phase 1 clinical trials". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 Jul · Business
Press release dated July 05, 2007, titled "Suven Life Sciences presenting Pre-clinical data of their NCE's SUVN-502 and SUVN-507 at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience to be held at Melbourne, Australia". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jun 2007
11 Jun · Business
Press release dated June 11, 2007, titled "Suven's Unit-III receives US FDA Acceptance". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Jun · Miscellaneous
Our Company's CEO Mr Venkat Jasti gave information in live interview with NDTV at 3.00 p.m. today (i.e. June 04, 2007) about filing of Investigational New Drug (IND) application in the therapeutic areas of Alzheimer in the month of June / July 07 and one more for Obesity is expected to be filed in next March / April 08
May 2007
3 May · Grant of Stock Options
The Compensation Committee met on May 3, 2007 at the Registered Office of the Company and granted 1,00,000 options to the eligible employees under the Employees Stock Option Plan - 2004 of the Company
Apr 2007
26 Apr · Business
Press release dated April 26, 2007, titled "Suven's yearly revenues Increase by 38%; PAT up by 33%; R&D spend at 24% of Revenue". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Apr · Board meeting
Meeting on 26 Apr 2007: “Unaudited Financial Results for the Qtr ended March 31, 2007”9 Apr · Corporate action
Share Transfer Committee of Board of Directors of the Company in its meeting held on April 06, 2007, has issued and allotted 5,76,33,250 equity shares of Re.1/- each in the ratio of (1:1) one equity share for every one equity share held by the members of the Company as per the Register of Members as on the Record Date.2 Apr · Board meeting
A meeting of committee of Board of Directors of our company will be held on Friday 6th April ,2007 at 11.30 a.m. to consider and allot bonus shares in the ratio of 1:1 to the members of the Company whose names borne on the Register of Members as on the Record Date
Mar 2007
22 Mar · Miscellaneous
Option forms sent to the shareholders for crediting of share in Electronic form for sub-division of shares from face value of Rs.2/- each to face value of Rs.1/- each and for applying Bonus shares in electronic form. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 Mar · E-mail ID for Investor Complaints
Our Company has created an e-mail-ID- investorservices@suven.com for the grievance redressal division exclusively for the purpose of registering complaints by investors and also to take necessary follow-up action and the same has been updated in our company website12 Mar · Corporate action
The members in Extra-Ordinary General Meeting held on 10th March 2007 have approved the Sub-division of equity shares from the face value of Rs.2/- each to face value of Re.1.00/- each and issue of Bonus shares 1:1 i.e. one equity share for every one equity share held as on the Record Date. The Board of Directors in their meeting held on 10th March 2007 at 12.30 p.m. has announced April 02, 2007 as the Record Date for the purpose of Sub-division of equity shares from face value of Rs.2/- each in to face value of Rs.1.00 each and issue of Bonus shares i.e. one equity share for every one equity share held5 Mar · Board meeting
To consider and announce the Record Date for the purpose of sub-division of shares from Rs 2/- each to Re 1/- each as well as for issue of Bonus shares, subject to approval of the members in the ensuing Extra-Ordinary General Meeting to be held on March 10, 2007.
Feb 2007
16 Feb · Meeting
Notice of the Extra-Ordinary General Meeting of the Company to be held on March 10, 2007. The copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2007
29 Jan · News Release
News release dated January 29,2007, titled "Suven Income up by 35%, Spends 17% on R&D; Suven shares split from Rs 2 per share to Re. 1 per share and Issues bonus shares in the ratio of 1:1". A copy of the news release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.29 Jan · Corporate action
The Board of Directors in their meeting held on 29th January 2007 have considered and approved the following matters: 1) Taken on Records the Un-audited financial results for the quarter ended 31st December 2006. 2) Approved the sub-division of equity shares from Face Value of Rs 2/- each to Face Value of Rs 1/- each subject to approval of members in general meeting and other approvals, if any. 3) Approved issue of Bonus equity shares in the ratio of (1:1) One equity share for every One equity share held by the members of the company, subject to approval of members in general meeting and other approvals, if any. The Extra-Ordinary General Meeting of the Company will be held on Saturday, 10th March 2007 for aproval of sub-division of equity shares and issue of bonus shares to the members as on the Record Date to be announced by the Board. Compensation committee of the Board met on 29th January 2007 and allotted 91,625 equity shares under the stock option plans of the company to the employees who have exercised the stock options. With this allotment the paid up capital of the company has gone up from 2,87,25,000 shares of Rs.2/- each aggregating Rs. 5,74,50,000 to 2,88,16,625 shares of Rs.2/- each aggregating Rs. 5,76,33,250/-22 Jan · Board meeting
Inter alia, to consider the following. (1) Take on record the Un-audited Financial Results for the Quarter ended 31st December 2006. (2) To consider sub-division of equity shares and (3) To consider issue of Bonus shares.